Related Experiment Videos
Phase II study of mitoxantrone in untreated and previously minimally treated patients with metastatic soft tissue
I Quirt1, E Eisenhauer, V Bramwell
1Princess Margaret Hospital, Toronto, Ontario, Canada.
Cancer Treatment Reports
|November 1, 1987
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
A Population-based Study of Survival Impact of New Targeted and Immune-based Therapies for Metastatic or Unresectable Melanoma.
Clinical oncology (Royal College of Radiologists (Great Britain))·2018
Barriers to participation in clinical trials: a physician survey.
Current oncology (Toronto, Ont.)·2018
A phase II study of SB939, a novel pan-histone deacetylase inhibitor, in patients with translocation-associated recurrent/metastatic sarcomas-NCIC-CTG IND 200†.
Annals of oncology : official journal of the European Society for Medical Oncology·2015
Phase II trial of vorinostat in advanced melanoma.
Investigational new drugs·2014
First-line treatment of advanced ovarian cancer with paclitaxel/carboplatin with or without epirubicin (TEC versus TC)--a gynecologic cancer intergroup study of the NSGO, EORTC GCG and NCIC CTG.
Annals of oncology : official journal of the European Society for Medical Oncology·2012
Cisplatin as a first-line treatment in T2 and T3 bladder carcinoma.
Cancer treatment reports·1987
IV melphalan in children.
Cancer treatment reports·1987
Interactions of methotrexate and cyclophosphamide with the pharmacokinetics of 5-fluorouracil in an animal model.
Cancer treatment reports·1987
Phase II trial of rDNA alfa 2b interferon in patients with malignant carcinoid tumor.
Cancer treatment reports·1987
Doxorubicin distribution in human breast cancer.
Cancer treatment reports·1987
Phase I study of echinomycin.
Cancer treatment reports·1987
Targeting Cancer-Associated Fibroblasts with Small-Molecule Inhibitors: Molecular Mechanisms and Therapeutic Potential.
Drug design, development and therapy·2026
EGFR-antibody-decorated cancer-cell-membrane-coated MOF nanoplatform enables targeted delivery of the STING agonist diABZI for pancreatic cancer immunotherapy.
International journal of pharmaceutics: X·2026
Targeting MAT2A-S-adenosylmethionine (SAM) Axis Attenuates DNA Damage Response and Cancer Stemness to Increase Platinum Sensitivity in Ovarian Cancer.
bioRxiv : the preprint server for biology·2026